;

Auto Summaries - Sequence
Last updated: 2024 Nov 18
Total hit(s): 5415
S.No.
1
39447388
Corrigendum to "Middle East respiratory syndrome coronavirus-a 10-year (2012-2022) global analysis of human and camel infections, genomic sequences, lineages, and geographical origins" [International Journal of Infectious Diseases (2023), volume 131, 87-94].
N/A
Int J Infect Dis
2024 Oct 23
3.42
1
2
39321502
Corrigendum to "The significance of recurrent de novo amino acid substitutions that emerged during chronic SARS-CoV-2 infection: an observational study" [eBioMedicine, 2024;107:105273].
N/A
EBioMedicine
2024 Oct
6.49
1
3
39083043
Features of the SARS-CoV-2 KP.3 variant mutations.
N/A
Infect Dis (Lond)
2024 Jul 31
1.23
1
4
38961696
Is there an increased number of community-acquired pneumonia requiring drainage placement in children after COVID-19 pandemic in Italy?
N/A
Pediatr Pulmonol
2024 Jul 3
2.64
1
5
39030295
Deletion of V483 in the spike confers evolutionary advantage on SARS-CoV-2 for human adaptation and host-range expansion after a prolonged pandemic.
N/A
Cell Res
2024 Jul 19
10.9
1
6
38809158
Another variant another history: description of the SARS-CoV-2 KP.2 (JN.1.11.1.2) mutations.
N/A
Infect Dis (Lond)
2024 Jul
1.23
1
7
38664266
Correction: Detection of SARS-CoV-2 spike protein D614G mutation using muTGGE.
N/A
Mol Biol Rep
2024 Apr 25
2.19
1
8
38272241
N/A
2024 Apr
1
9
38048665
Fixation and reversion of mutations in the receptor-binding domain of SARS-CoV-2 spike protein.
N/A
Diagn Microbiol Infect Dis
2024 Feb
2.33
1
10
38219759
Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution.
N/A
Lancet Microbe
2024 Jan 11
- n/a -
1
11
38164631
The mutation point of view of the SARS-CoV-2 HV.1 lineage.
N/A
J Med Virol
2024 Jan
2.07
1
12
38224200
The roles of innate and adaptive immunity in inactivated viral vaccination-mediated protection against COVID-19.
N/A
Clin Transl Med
2024 Jan
4.08
1
13
38149407
No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir/ritonavir.
N/A
J Med Virol
2024 Jan
2.07
1
14
38129796
Correction: Near complete genome sequences from Southern Vietnam revealed local features of genetic diversity and intergenerational changes in SARS- CoV-2 variants in 2020-2021.
N/A
BMC Infect Dis
2023 Dec 21
2.58
1
15
37186902
Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.
SARS-CoV-2 causes significant morbidity and mortality in humans. One factor that may influence virus control is pre-existing immunity conferred by an individual's past exposures to endemic coronaviruses (eCOVIDs) The nations where continuous exposures to eCOVIs are very high due to religious and traditional causes showed significantly lower cases and low mortality rates per 100,000.
Libyan J Med
2023 Dec
2.8
1
16
36820816
The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection.
Anti-SARS-CoV-2S antibody levels were measured (ECLIA assay) in 50 healthcare workers with and without a history of COVID-19 infection to determine the humoral immune response to the third dose of the BNT162b2 vaccine. Age, gender, BMI, type work, type of work, and presence of comorbidities may be associated with different humoral immunizations. The results of this study can be used to improve the vaccination strategy for the general population.
Ann Med
2023 Dec
3.01
1
17
36788502
Novel COVID-19 vaccine hesitancy and acceptance, and associated factors, amongst medical students: a scoping review.
Medical students are likely to be exposed to COVID-19 patients so achieving high vaccination coverage rates for this group of healthcare workers is important. The aim of this scoping review was to evaluate the current literature to determine the rates of vaccine hesitancy and acceptance, and associated factors, amongst medical students.
Med Educ Online
2023 Dec
3.7
1
18
36426608
Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses.
N/A
Emerg Microbes Infect
2023 Dec
5.84
1
19
36715323
Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
A test-negative case-control study was conducted among adults (age >/=18 years) who were at-risk for COVID-19 and presented for nasopharyngeal real-time polymerase chain reaction testing during the Omicron variant-dominant period in Thailand (1 January 2022-15 June 2022) The highest VE were observed in individuals receiving the 4-dose regimen,. preventing infection (65%) and preventing moderate-to-critical diseases (82%) The heterologous boosters with viral vector and mRNA vaccines were highly effective and can be used in individuals who previously received the primary series of inactivated vaccine.
Emerg Microbes Infect
2023 Dec
5.84
1
20
37144395
Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
The main protease (3-chymotrypsin-like protease, 3CLpro) of SARS-CoV-2 has become a focus of anti-coronavirus research. Despite efforts, drug development targeting 3CLPro has been hampered by limitations in the currently available activity assays. Here, we report an orthogonal dual reporter-based gain-of-signal assay for measuring 3Clpro activity in living cells. This assay circumvents most limitations in previously reported assays, especially false positives caused by nonspecific compounds and signal interference from test compounds.
Emerg Microbes Infect
2023 Dec
5.84
1
21
36715434
Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients.
Study aimed to identify adverse events following the first three doses of COVID-19 vaccines in hemodialysis patients. Overall, 79%, 50% and 84% of the participants experienced at least one adverse event after their first, second, and third doses. Age, sex, dialysis vascular access and vaccine types were associated with postvaccination adverse events.
Ren Fail
2023 Dec
1.68
1
22
37114433
Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism.
A triple deletion (DeltaSGF or DeltaLSG) in nonstructural protein 6 augments nsp6-mediated antagonism of type-I interferon (IFN-I) signaling. The impact of mutations outside the Spike gene are poorly understood, but they may alter pathogenesis of SARS-CoV-2 variants in humans. Analyses of host responses from DeltaSGF-WA1-infected mice and primary airway cultures reveal activation of pathways indicative of a cytokine storm.
Emerg Microbes Infect
2023 Dec
5.84
1
23
37272331
An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.
The neutralizing activity of the human serum after Omicron-based vaccine booster against different SARS-CoV-2 variants is poorly understood. We developed a dose updated vaccine (SCoK-Omicron) based on the RBD-Fc fusion protein vaccine and RBD domain of Omicrons BA.1.1. Further assays of single point mutations showed that K444T, L452R, N460K, or F486V was key mutations to cause immune evasion.
Emerg Microbes Infect
2023 Dec
5.84
1
24
36594480
COVID-19 vaccine hesitancy between family decision-makers and non-decision-makers among college teachers.
A cross-sectional online survey was administered across mainland China from 4 to 7 August 2021. Overall, 42.2% of the teachers were hesitant to being vaccinated against COVID-19. The hesitancy rate was lower among primary decision-makers than that among non-decision-makers. Those engaged in nursing education versus non-medical related professional education (OR = 2.67, 95% CI 1.29-5.49) were more likely to be hesitant.
Ann Med
2023 Dec
3.01
1
25
37929659
Mutational analysis of severe acute respiratory syndrome coronavirus 2 in immunocompromised patients with persistent viral detection using whole genome sequencing.
N/A
Clin Transl Med
2023 Nov
4.08
1